Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors
June 16, 2022 09:50 ET
|
Curative Biotechnology, Inc.
Appointment of Independent Director Builds Upon Biotech Expertise Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a...
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors
May 12, 2022 09:30 ET
|
Curative Biotechnology, Inc.
Appointment of Independent Director Adds to Financial Expertise on Board Boca Raton, FL, May 12, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the...
Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration
May 03, 2022 09:30 ET
|
Curative Biotechnology, Inc.
National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA) Boca Raton, FL, May 03, 2022 (GLOBE NEWSWIRE) -- Curative...
Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration
March 21, 2022 09:50 ET
|
Curative Biotechnology, Inc.
Emily Y. Chew, M.D. of the National Eye Institute Assigned Principal Investigator Boca Raton, FL, March 21, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the...
[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
November 24, 2021 15:05 ET
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
November 24, 2021 10:00 ET
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO
October 12, 2021 10:12 ET
|
Curative Biotechnology, Inc.
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-related Macular Degeneration Boca Raton, FL, Oct. 12, 2021 ...
CURATIVE BIOTECHNOLOGY ANNOUNCES IMT504 LICENSE FOR DEVELOPMENT OF PROPRIETARY NEXT-GEN COVID-19 VACCINE
October 07, 2021 10:20 ET
|
Curative Biotechnology, Inc.
License from Mid-Atlantic BioTherapeutics for IMT504 Broadens Scope of Initial License Beyond Treatment of Symptomatic Rabies Boca Raton, FL, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Curative...
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board
September 02, 2021 10:10 ET
|
Curative Biotechnology, Inc.
Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Expertise in Neurobiology Boca Raton, FL, Sept. 02, 2021 (GLOBE NEWSWIRE) --...
Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee
July 15, 2021 10:00 ET
|
Curative Biotechnology, Inc.
Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for...